KSQ-004EX

Phase 2Small molecule

MM.D. Anderson Cancer Center

KSQ-004EX is one of 16 small molecule programs targeting Tumor Infiltrating Lymphocytes. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Tumor Infiltrating LymphocytesRecruiting

Tumor Infiltrating LymphocytesPhase 2

Recruiting

Competition

Competitive Landscape

16 competitors in Tumor Infiltrating Lymphocytes

#DrugCompanyPhaseTrials

Abraxane

Bristol-Myers Squibb

Phase 2

1 2

Yervoy

Bristol-Myers Squibb

Phase 2

1 3

Keytruda

Merck & Co.

Phase 2

1 4

Taxol

Teva

Phase 2

1 5

Fludara

Sanofi

Phase 2

1 6

Opdivo

Bristol-Myers Squibb

Phase 2

1 7

Paraplatin

AAvyxa

Phase 2

1 8

Alimta

SShawn Eagle

Phase 2

1 9

Cytoxan

BBaxter Healthcare Corporation

Phase 2

1 10

Amtagvi

IIovance Biotherapeutics, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2041

Phase 1/2Recruiting

Tumor Infiltrating Lymphocytes

NCT06598371

Clinical

Trials by Indication[1]

Tumor Infiltrating Lymphocytes1 trial

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT06598371·141 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for KSQ-004EX. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KSQ-004EX compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KSQ-004EX. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MM.D. Anderson Cancer Center

KSQ-004EX

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2041

Trials by Indication[1]

Tumor Infiltrating Lymphocytes1 trial

References

Drug Info

Quick Facts

Related News